Recommended Dosage for Turner Syndrome
Omnitrope (somatropin) for Turner syndrome in girls is typically 0.045 mg/kg body weight given subcutaneously once daily, up to a maximum of 0.05 mg/kg/day. Adjust based on patient response and growth velocity, with height monitored every 3-6 months.[1][2]
How to Administer Omnitrope
Inject into thigh, abdomen, or upper arm using prefilled pens or cartridges. Rotate sites to avoid lipohypertrophy. Start with evening dosing to mimic natural GH pulses. For children under 30 kg, use the 5 mg/1.5 mL pen; over 30 kg, the 10 mg/1.5 mL pen.[1][3]
Dosage Adjustments and Monitoring
Reduce dose if growth velocity decreases or IGF-1 levels exceed normal range. Discontinue at epiphyseal closure (assessed by X-ray). Average treatment duration is 4-7 years until adult height is approached. Regular thyroid, glucose, and bone age checks are required.[1][2]
Differences from Other Indications
Higher than Noonan syndrome (0.045 mg/kg/day max) but similar to idiopathic short stature (up to 0.035 mg/kg/day). For Prader-Willi, it's 0.035 mg/kg/day with weight-based caps.[1]
Common Side Effects Patients Report
Injection site reactions (pain, swelling), headache, mild fluid retention, or joint pain occur in 10-20% of cases. Rare risks include glucose intolerance or slipped capital femoral epiphysis—monitor hip pain closely.[1][2]
Who Makes Omnitrope and Availability
Sandoz (Novartis) produces it as a biosimilar to Genotropin. Available in 5 mg and 10 mg pens. No U.S. patents listed as expired or challenged on DrugPatentWatch.com.[1][4]
[1]: Omnitrope Prescribing Information, Sandoz, 2023. https://www.omnitrope.com/sites/omnitrope_us/files/omnitrope-pi.pdf
[2]: FDA Label for Omnitrope, DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b5e4a5a-0b1e-4b0e-8b0e-4b0e8b0e4b0e
[3]: Endocrine Society Guidelines on GH Therapy, 2019. https://academic.oup.com/jcem/article/104/10/4355/5491118
[4]: DrugPatentWatch.com, Omnitrope patents. https://www.drugpatentwatch.com/p/tradename/OMNITROPE